Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06845319 2026-05-06

NeoCARD

Phase 2 Recruiting

43 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04317534 2026-05-05

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Phase 2 Recruiting

244 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04430699 2026-05-05

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Phase 2 Active not recruiting

24 enrolled

Gynecologic

Vulvar Neoplasms

NCT05956041 2026-05-05

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Phase 2 Recruiting

23 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT07017829 2026-05-05

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Phase 2 Recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02641093 2026-05-04

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

96 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT03752333 2026-05-04

CUPem

Phase 2 Completed

35 enrolled 11 charts

Tumor-Agnostic

Carcinoma, Neoplasms, Neoplasms, Unknown Primary

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

240 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05379972 2026-05-04

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Phase 2 Active not recruiting

9 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT07037004 2026-05-04

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Phase 2 Not yet recruiting

62 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06180733 2026-05-01

PAM-II

Phase 2 Active not recruiting

12 enrolled

GynecologicLymphoid

Lymphoma, Follicular, Uterine Neoplasms, Endometrial Neoplasms

NCT05358548 2026-04-30

ATATcH Alternating Treatment Plans for Advanced Cancer

Phase 2 Recruiting

150 enrolled

Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT05384015 2026-04-30

PEERS

Phase 2 Active not recruiting

46 enrolled

Thoracic

Lung Neoplasms

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

110 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04887805 2026-04-29

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Phase 2 Active not recruiting

28 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

PROMPT

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

PEM-PRO

P+R-ICE

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

PLANE-PC

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

RECIPE-B1

NEO COMBAT XL

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

I-SPY

SPiReL

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

NeoCARD

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

CUPem

SAMURAI

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

PAM-II

ATATcH Alternating Treatment Plans for Advanced Cancer

PEERS

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer